Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/22/2012 | 07:32pm CET
   By Jon Kamp 
 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
12/15 MERCK AND : University of Akron research promising in opioid fight
12/14 MERCK : Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizu..
12/14 MERCK AND : PREVYMIS™ (letermovir) Available in Canada in Late December 20..
12/14 MERCK AND COMPANY : ex-dividend day
12/13 MERCK AND : FDA Accepts Supplemental Biologics License Application, Assigns Prio..
12/13 MIT's LEAPS pilot aims to integrate data generation
12/13 Aduro discontinues development of CRS-207
12/12 MERCK AND : Polymer Professor Awarded $2 Million for Leading Research in Fightin..
12/12 MERCK AND : raises stakes in lung cancer treatments as rivals start to close in
12/11 MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
More news
News from SeekingAlpha
12/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 16, 2017
12/16 Stocks to watch next week
12/15 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Merck's Keytruda flunks late-stage study in second-line gastric cancer
12/14 Test Portfolio Results And Introducing A New Quality Portfolio
Financials ($)
Sales 2017 40 231 M
EBIT 2017 13 720 M
Net income 2017 5 277 M
Debt 2017 13 787 M
Yield 2017 3,36%
P/E ratio 2017 27,55
P/E ratio 2018 18,13
EV / Sales 2017 4,16x
EV / Sales 2018 4,04x
Capitalization 153 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,4 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-4.86%153 386
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
AMGEN21.32%128 515